in vitro News and Research

RSS

New combination therapy could overcome treatment resistance, relapse in breast cancer

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.

21 Apr 2015

Insulin signaling pathway has significant influence on the growth of glioblastomas

Drugs that target insulin pathways to slow or stop the growth of brain tumors are going in the right direction but appear to be on the wrong track, according to new research at Rice University.

21 Apr 2015

Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency - long associated with numerous diseases, e.g. autism, lung cancer, prostate cancer, and ovarian cancers - can lead to activation of the Hedgehog signaling pathway, a biomolecular pathway that plays essential roles in developing organisms and in diseases, according to new research at Rensselaer Polytechnic Institute.

17 Apr 2015

Electronic micropump combined with anticonvulsant drug may treat brain diseases

Many potentially efficient drugs have been created to treat neurological disorders, but they cannot be used in practice. Typically, for a condition such as epilepsy, it is essential to act at exactly the right time and place in the brain.

16 Apr 2015

Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid and FIND today announced that Xpert HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

16 Apr 2015

Houston Methodist researchers discover new, ex vivo lung cancer model to study tumor progression

Without good models to study cancer metastasis -- the spread of cancer cells from one organ to another -- cancer researchers have struggled to understand tumor progression fully, and new therapies targeting the main causes of death are slow to come.

16 Apr 2015

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics, today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.

From Quest Diagnostics 15 Apr 2015

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.

15 Apr 2015

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd.

14 Apr 2015

LaVision BioTec reports on the Beatson Institute for Cancer Research and their use of multiphoton microscopy to understand the behaviour of cells in cancer metastasis

LaVison BioTec, developers of advanced microscopy solutions for the life sciences, report on the research of Professor Kurt I Anderson and his groups' studies of cell migration in the context of cancer metastasis at the Beatson Institute for Cancer Research...

14 Apr 2015

Fraunhofer researchers develop cell-free substrate made of advanced fibers

Regenerative medicine uses cells harvested from the patient's own body to heal damaged tissue. Fraunhofer researchers have developed a cell-free substrate containing proteins to which autologous cells bind and grow only after implantation.

10 Apr 2015

BioTek to exhibit at American Association for Cancer Research 2015

BioTek Instruments will demonstrate their latest microplate-based imaging, detection and liquid handling solutions for cancer research at the AACR Annual Meeting to be held April 18-22 in Philadelphia, Pennsylvania.

9 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

The Journal of Drugs in Dermatology is pleased to publish findings on a new injectable drug currently under development by Kythera Biopharmaceuticals, Inc. (Westlake Village, CA) that may provide a non-surgical alternative for people with double chins.

6 Apr 2015

New biodegradable membrane reduces wound healing time by 50%

Treatments to regenerate skin from burns become tedious and long lasting; however, Mexican researchers developed a biodegradable membrane that allows to transfer skin cells (keratinocytes) to burn wounds, when placed on the wound. The method reduces healing time by 50 percent.

3 Apr 2015

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Experimental Therapeutics, at the Perelman School of Medicine at the University of Pennsylvania, was named one of 16 finalists in the first phase of the Follow that Cell Challenge funded by the National Institutes of Health. The competition was run by crowdsourcing company Innocentive and 687 designated "solvers" entered initially.

2 Apr 2015

Novel molecule inhibits cancer-causing transcription factors

A novel molecule designed by scientists at the University of Massachusetts Medical School and the University of Virginia inhibits progression of a hard-to-treat form of recurring acute myeloid leukemia (AML) in patient tissue.

2 Apr 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found.

1 Apr 2015

Research breakthrough could help develop tools to repair damaged nerve cells

A team of researchers at the IRCM led by Frédéric Charron, PhD, in collaboration with bioengineers at McGill University, uncovered a new kind of synergy in the development of the nervous system, which explains an important mechanism required for neural circuits to form properly.

1 Apr 2015

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

Scientists from the Florida campus of The Scripps Research Institute have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects.

1 Apr 2015

in vitro News and Research

New combination therapy could overcome treatment resistance, relapse in breast cancer

Insulin signaling pathway has significant influence on the growth of glioblastomas

Zinc deficiency can activate Hedgehog signaling pathway

Electronic micropump combined with anticonvulsant drug may treat brain diseases

Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Houston Methodist researchers discover new, ex vivo lung cancer model to study tumor progression

Focus Diagnostics announces FDA clearance for Simplexa Group A Strep Direct Kit

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

LaVision BioTec reports on the Beatson Institute for Cancer Research and their use of multiphoton microscopy to understand the behaviour of cells in cancer metastasis

Fraunhofer researchers develop cell-free substrate made of advanced fibers

BioTek to exhibit at American Association for Cancer Research 2015

Nabriva Therapeutics completes $120 million Series B financing

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

New biodegradable membrane reduces wound healing time by 50%

Penn Med's BLINKER Team named one of 16 finalists in NIH 'Follow that Cell Challenge'

Novel molecule inhibits cancer-causing transcription factors

Low doses of imatinib drug can push immune system to combat bacterial infections

Research breakthrough could help develop tools to repair damaged nerve cells

TSRI scientists uncover unique mechanism of natural product with antimicrobial, anti-cancer effects

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News